肝移植后基于他克莫司（FK506）的双重与三重疗法 - Suppr | 超能文献

Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation.

作者信息

Samuel D, Bismuth H, Boillot O, Ducerf C, Baulieux J, Gugenheim J, Baldini E, Launois B, Messner M, Wolf P, Ellero E, Domergue J, Pageaux J, Cherqui D, Duvoux C, Durand F, Belghiti J, Calmus Y, Massault P P, Neau-Cransac M, Saric J, LeTreut Y, Campan P

机构信息

Hospital P. Brousse, Villejuif, France.

出版信息

Transplant Proc. 1998 Jun;30(4):1394-6. doi: 10.1016/s0041-1345(98)00286-3.

DOI:10.1016/s0041-1345(98)00286-3

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation.肝移植后基于他克莫司（FK506）的双重与三重疗法

Transplant Proc. 1998 Jun;30(4):1394-6. doi: 10.1016/s0041-1345(98)00286-3.

2

Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation.在肝移植中，基于他克莫司的双重疗法与传统的基于他克莫司的三联疗法一样有效且安全。

Transplant Proc. 2001 May;33(3):2258-62. doi: 10.1016/s0041-1345(01)01983-2.

3

FK506 for primary and rescue therapy following liver transplantation.

Transplant Proc. 1998 Jun;30(4):1409-10. doi: 10.1016/s0041-1345(98)00293-0.

4

Low rejection rates with tacrolimus-based dual and triple regimens following liver transplantation.肝移植后基于他克莫司的二联和三联方案排斥反应发生率低。

Clin Transplant. 2001 Jun;15(3):159-66. doi: 10.1034/j.1399-0012.2001.150303.x.

5

Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation.肝移植后抗体诱导治疗联合他克莫司免疫抑制的风险与获益

Transplant Proc. 1998 Jun;30(4):1443-4. doi: 10.1016/s0041-1345(98)00308-x.

6

Five-year follow-up of tacrolimus as primary immunosuppressant after liver transplantation.肝移植后使用他克莫司作为主要免疫抑制剂的五年随访

Transplant Proc. 1998 Aug;30(5):2179-81. doi: 10.1016/s0041-1345(98)00580-6.

7

Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: complete report on 350 primary adult liver transplantations.他克莫司与泼尼松联用对比他克莫司、泼尼松及霉酚酸酯的前瞻性随机试验：350例成人原位肝移植完整报告

Transplant Proc. 2001 Feb-Mar;33(1-2):1342-4. doi: 10.1016/s0041-1345(00)02502-1.

8

Quadruple versus dual tacrolimus-based induction after liver transplantation: a prospective, randomized trial.

Transplant Proc. 2001 May;33(3):2330-1. doi: 10.1016/s0041-1345(01)02011-5.

9

Low incidence of acute cellular rejection in liver transplantation with Neoral.使用新山地明（Neoral）进行肝移植时急性细胞排斥反应的发生率较低。

Transplant Proc. 1998 Aug;30(5):1854. doi: 10.1016/s0041-1345(98)00456-4.

10

Tacrolimus is effective in both dual and triple regimens after liver transplantation.

Transplant Proc. 2002 Aug;34(5):1529-30. doi: 10.1016/s0041-1345(02)03006-3.

引用本文的文献

1

Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis.成人肝移植受者的诱导免疫抑制：一项网状Meta分析。

Cochrane Database Syst Rev. 2020 Jan 16;1(1):CD013203. doi: 10.1002/14651858.CD013203.pub2.

2

Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.他克莫司：其在器官移植管理中的药理学及治疗应用的进一步更新

Drugs. 2000 Feb;59(2):323-89. doi: 10.2165/00003495-200059020-00021.